

Luminesce Alliance Functional Genomics Enabling Platforms

The Luminesce Alliance Functional Genomics Enabling Platform provides subsidised support services for translational research projects in paediatric precision medicine, encompassing research activity in research genomics, genomic medicine, regenerative medicine and advanced therapeutics across genetic diseases, neurodevelopmental disorders and cancers.

Expression of Interest (EOI)

The Functional Genomics Enabling Platform is open to precision medicine research teams of Luminesce Alliance partner organisations (Sydney Children's Hospitals Network, Children's Medical Research Institute, Children's Cancer Institute, University of NSW, University of Sydney) requiring subsidised functional genomics research services. The Expression of Interest (EOI) supports three key paediatric precision medicine research streams:

- (1) Inherited retinal disorders and vision impairment
- (2) Neurodevelopmental disorders
- (3) Telomere disorders - haematological diseases and bone marrow failure.

Other new or merging disease streams where the Enabling Platform can deliver new research capacity across stem cell medicine and vectorology may also be considered.

The Enabling Platform will consider the expression of interest (EOI) to access the following facilities:

- Research Genomics: biochemical genetics, proteomics, metabolomics
- Single-Cell Omics Analytics
- Stem Cell and Organoid Facility
- Genome Engineering
- Vector Engineering
- Advanced imaging
- Functional Genomics Data Analytics

Information of the research capacity of the facilities can be found at: [Luminesce Alliance Functional Genomics Enabling Platforms](#)

The EOI should address the relevance of the research project for precision medicine based on the three key paediatric precision medicine research streams outlined above and specify the requisite support from the Functional Genomics Enabling Platform for enhancing the delivery of research outcome. EOI's are to be submitted via email to: researchfacilities@cmri.org.au

The EOI will be evaluated by the scientific panel of the Enabling Platform for suitability and feasibility of subsidised support. The investigator will be advised on the outcome of evaluation within 15 working days after submission of the EOI.

Following a successful EOI, investigators will need to prepare a project proposal defining the scope of work. This allows the Functional Genomics Enabling Platform to plan the provision of service (incorporating resource availability and the timeline and costing of the service). Work will commence when the project proposal is approved by the Platform and the plan of service provision is accepted by the investigator. Services provided by the Enabling Platform are subsidised services, and some costs to researchers will be incurred.

Inquiries may be directed to:

CMRI Scientific Facilities Engagement and Service Support email: researchfacilities@cmri.org.au or Patrick Tam, Lead Investigator, Functional Genomics Enabling Platform email: ptam@cmri.org.au

SECTION A – Investigator

Luminesce Alliance Affiliation

Children's Cancer Institute Children's Medical Research Institute University of Sydney
Sydney Children's Hospitals Network University of New South Wales

Paediatric Precision Medicine Stream

Inherited retinal disorders and vision impairment Neurodevelopmental disorders
Telomere disorders - haematological diseases and bone marrow failure
Other - Please specify

Investigator name

Contact details:

Email

Phone

Other Investigator(s) involved in the proposed research

Name

Organisational affiliation

SECTION B - PROJECT OVERVIEW

Project title *(Max 15 words)*

Research question/s addressed by this project

Project summary *(Max 300 words)*

Anticipated deliverables

SECTION B - Continued

Funding available from other sources for this research project

Yes (Please specify source and amount)

No / Part Funded (Please specify the scope of work that requires funding by the Platform)

Have the materials and methods for the work of this project covered by ethics approval, material transfer agreement, and intellectual property?

Yes, submitted waiting approval

No. Please specify expected timeline for approvals

Anticipated project work and delivery timeline

END OF FORM